MedTrace Logo

Effect of Dexmedetomidine Combined With Low-dose Nalmefene on Preventing Remifentanil-induced Postoperative Hyperalgesia

NCT03096730 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2021-08-03

Study results available
· View outcomes & findings →

Summary

To explore and compare antihyperalgesic effects of Dexmedetomidine,Nalmefene,and a combination of both received before anesthesia induction.

To evaluate and examine the incidence of adverse effects with the purpose of selecting the optimum dose.

Conditions

Interventions

DRUG

Normal saline

Normal saline is intravenously administrated before anesthesia induction

DRUG

Remifentanil

Remifentanil is intravenously administrated

DRUG

Sufentanil

Sufentanil is intravenously administrated

DRUG

Dexmedetomidine injection

Dexmedetomidine is intravenously administrated before anesthesia induction

DRUG

Nalmefene

Nalmefene is intravenously administrated before anesthesia induction

Sponsors & Collaborators

  • Tianjin Medical University General Hospital

    lead OTHER

Principal Investigators

  • Wang Guolin, MD · Tianjin Medical University General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-06
Primary Completion
2017-12-20
Completion
2017-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03096730 on ClinicalTrials.gov